Magnetic Resonance investigation into the mechanisms involved in the development of high-altitude cerebral edema by Sagoo, RS et al.
Original Article
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Abstract
Rapid ascent to high altitude commonly results in acute mountain sickness, and on occasion potentially fatal high-altitude
cerebral edema. The exact pathophysiological mechanisms behind these syndromes remain to be determined. We report a
study in which 12 subjects were exposed to a FiO2¼ 0.12 for 22h and underwent serial magnetic resonance imaging sequences
to enable measurement of middle cerebral artery velocity, flow and diameter, and brain parenchymal, cerebrospinal fluid and
cerebral venous volumes. Ten subjects completed 22 h and most developed symptoms of acute mountain sickness (mean Lake
Louise Score 5.4; p< 0.001 vs. baseline). Cerebral oxygen delivery was maintained by an increase in middle cerebral artery
velocity and diameter (first 6 h). There appeared to be venocompression at the level of the small, deep cerebral veins (116 cm3
at 2 h to 97 cm3 at 22 h; p< 0.05). Brain white matter volume increased over the 22-h period (574ml to 587ml; p< 0.001) and
correlatedwith cumulative Lake Louise scores at 22h (p< 0.05).We conclude that cerebral oxygen delivery wasmaintained by
increased arterial inflow and this preceded the development of cerebral edema. Venous outflow restriction appeared to play a
contributory role in the formation of cerebral edema, a novel feature that has not been observed previously.
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Introduction
On ascent to altitude, there is a reduction in barometric
pressure and a consequent fall in the partial pressure of
inspired oxygen.1–3 Acute mountain sickness (AMS) of
varying severity can develop in individuals following
rapid ascent to high altitudes.1,4 The symptoms of
AMS encompass a wide range of signs and symptoms,
the most prominent of which include headache,
vomiting, lethargy, and cerebral dysfunction.1,2 At the
extreme end of the spectrum, there is a risk of the
potentially fatal high-altitude cerebral edema (HACE)
and high-altitude pulmonary edema (HAPE)
developing.5,6
The brain is particularly sensitive to a lack of oxygen
and, therefore, several adaptive mechanisms are
believed to occur to maintain adequate oxygen delivery.
1Department of Imaging, University Hospitals Coventry and
Warwickshire NHS Trust, Coventry, West Midlands, UK
2Warwick Medical School, University of Warwick, Coventry, West
Midlands, UK
3College of Medical and Dental Sciences, University of Birmingham,
Birmingham, UK
4University Hospitals Birmingham NHS Foundation Trust, Birmingham,
UK
5Division of Health Sciences, Warwick Medical School, University of
Warwick, Coventry, West Midlands, UK
6Department of Medical Physics, University Hospitals Coventry and
Warwickshire NHS Trust, Coventry, West Midlands, UK
7Department of Neurosurgery, Imperial College Healthcare NHS Trust,
London, UK
8Department of Surgery, University Hospitals Coventry and
Warwickshire NHS Trust, Coventry, West Midlands, UK
9Coventry University, West Midlands, UK
Corresponding author:
Christopher HE Imray, Department of Surgery, University Hospitals
Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, West
Midlands, UK.
Email: chrisimray@aim.com
Journal of Cerebral Blood Flow &
Metabolism
0(00) 1–13
! Author(s) 2016
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/0271678X15625350
jcbfm.sagepub.com
Over a variable time course, hyperventilation, increased
heart rate, increased blood pressure, a rise in the hem-
atocrit and hemoglobin are all known to facilitate
cerebral oxygen delivery (COD).7 Speciﬁc to the brain,
Wilson et al.8 suggested that both a rise in middle cere-
bral artery (MCA) diameter and ﬂow velocity are
responsible for a rise in cerebral blood ﬂow (CBF) in
sustained hypoxia. Until recently, cerebral arterial diam-
eter was widely assumed to stay constant, while cerebral
ﬂow velocity was thought to be the sole responsible
factor in maintaining cerebral oxygenation.9
The exact pathophysiological mechanisms in the
development of AMS and HACE have yet to be fully
determined. One of themain theories to explain the devel-
opment of AMS is an increase in intracranial pressure
(ICP).3 Direct ICP measurement is diﬃcult to achieve in
healthy volunteers, but the ICP can be inferred indirectly
via volume alterations in the diﬀerent intracranial tis-
sues.10,11 Hackett et al.12 have alluded to the development
of cerebral edema and its association with AMS in vol-
unteers subjected to sustained hypoxia, particularly
within the corpus callosum. Other studies have shown
development of cerebral edema, as well as increases in
brain parenchymal volume and compensatory decreases
in cerebrospinal ﬂuid (CSF) volume in volunteers sub-
jected to sustained hypoxia, but these changes were seen
in patients both with and without AMS.13
Vasogenic (extracellular water accumulation due to
increased permeability of the blood–brain barrier)12 and
cytotoxic (intracellular)14 edema have been postulated as
the mechanisms that underlie HACE. Whether AMS is a
milder form of vasogenic and/or cytotoxic, edema
remains unclear. However, the rise in parenchymal
volume or decrease in CSF volume could also be due to
a rise in the CBF and/or eﬀerent restriction of cerebral
venous outﬂow, thus increasing the ICP.15 In a high-
altitude study, Wilson et al.16 showed that the headache
burdenwas positively related to the retinal vein distension
and individuals with relatively narrow transverse sinuses
were more prone to hypoxia-induced headaches.
We undertook a sea-level study to observe the eﬀects
of normobaric hypoxia in healthy individuals on the
brain and cerebral vasculature over a prolonged
period of 22 h (AMS and HACE normally take
12–24 h to develop), making multiple assessments to
assess the time course of aspects of cerebral perfusion
that might be implicated in the development of HACE.
We assessed a uniﬁcation hypothesis of two separate
concepts to explain the development of HACE: ﬁrstly,
the raised arterial inﬂow (with cytotoxic and vasogenic
edema) and, secondly, restricted venous outﬂow the-
ories.15 This uniﬁcation hypothesis was ﬁrst proposed
in schematic format in 2009.3 Speciﬁcally, we aimed to
study changes in the cerebral arterial caliber and ﬂow vel-
ocity, changes in the small cerebral venous and dural
venous sinus caliber, observe the time course of the devel-
opment of cerebral edema and volume alterations of the
brain parenchyma and intracranial CSF. A novel feature
of this study was that these variables were measured
repeatedly and simultaneously over a 22-h period of sus-
tainedhypoxia,which has not beenperformed previously.
Materials and methods
Subjects and study design
The study design was a prospective observational
cohort study, in which subjects were exposed to
normobaric hypoxia in a chamber setting. Subjects
self-assessed clinical symptoms and various magnetic
resonance (MR) sequences were used to assess changes
in cerebral parameters. Coventry and Warwickshire
NHS Research Ethics Committee provided ethical
approval for this study. Written informed consent was
obtained from each study participant.
Twelve subjects (10 males, mean age: 26.2 years,
range: 21–47 years) were studied over a continuous
normobaric hypoxic period of 22 h. None of the sub-
jects had ascended> 1000m in the preceding six
months. Subjects were students interested in wilderness
medicine and recruited by word of mouth.
Hypoxia
Subjects were exposed to 22 h of continuous normoba-
ric hypoxia (FiO2¼ 0.12, approximately equivalent to
an altitude of 4400m) inside a 2m 2m 1.6m
hypoxic tent. Three hypoxic generators were used
(Everest Summit Hypoxic Generator, Hypoxic
Systems, New York, NY, USA). Build-up of carbon
dioxide within the tent was controlled with an air
pump (Bair HuggerTM, 3M, Berkshire, UK), which
pumped the tent air through a two soda lime scrubber
(SpherasorbTM – medical grade soda lime from
Intersurgical Ltd UK in canisters by Draeger Medical
UK Ltd). The soda lime was replaced at 12 h. Baseline
physiological measurements, venous blood samples,
and magnetic resonance imaging (MRI) scans were
obtained at normoxia (FiO2¼ 0.21). Inspired oxygen
and carbon dioxide concentrations were checked
every 15min for the ﬁrst 2 h, every 30min from
2–10 h, and then every 2 h from 12–22 h. Extended
MRI compatible tubing and a tight ﬁtting mask that
were connected to one of the three hypoxic generators
enabled the subjects to remain hypoxic during the MRI
studies. The subjects were scanned at rest and did not
undertake exercise during the study period.
Subjects ate and drank ad libitum were kept well
hydrated and slept at various points between the 12
and 22-h time points.
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Physiological measurements
Physiological measurements were obtained at baseline
followed by 2, 4, 6, 11, and 22 h of continuous normo-
baric hypoxia. Blood pressure was measured using an
automated cuﬀ, peripheral arterial oxygen saturation
(SaO2) and heart rate by near infrared ﬁnger pulse
oximetry probe, and end tidal carbon dioxide
(ETCO2) using an infrared capnometer (Dash 3000,
GE Medical Systems, Wisconsin, USA).
Whole venous blood samples were obtained at base-
line, 11 and 22 h of continuous normobaric hypoxia.
Laboratory analysis of hematological (hematocrit and
concentration of hemoglobin (Hb), red blood cells,
white blood cells, and platelets), biochemical (concen-
tration of sodium, potassium, urea, and creatinine) and
inﬂammatory variables (erythrocyte sedimentation rate
(ESR), and concentration of C-reactive protein (CRP))
was carried out on each sample.
Blood oxygen content (BOC) and MCA ﬂow (f) were
calculated using equations (1) and (2), respectively.
BOC ¼ 1:36 Hb  SaO2 ð1Þ
f ¼  d
2
 2
v ð2Þ
where d is the MCA diameter and v the MCA ﬂow
velocity.The COD was determined using equation (3).
COD ¼ BOC  f ð3Þ
Headache and Lake Louise scores
The Lake Louise questionnaire and scoring system
were used to assess symptoms associated with AMS
at baseline and 2, 4, 6, 11, and 22 h of continuous
12% normobaric hypoxia.17 A total Lake Louise
score of >3 including headache at any time point was
deﬁned as AMS. Cumulative Lake Louise scores were
calculated by adding the Lake Louise scores at each
time point to give a total score for each subject.
MRI
Each subject underwent 3-T MRI scanning (GE Signa
HDxt, Milwaukee, USA) at baseline, and 2, 4, 6, 11,
and 22 h of continuous normobaric 12% hypoxia. The
following sequences were obtained:
1. 3D time of ﬂight (TOF) magnetic resonance angiog-
raphy (MRA) of the circle of Willis was performed to
enable measurement of MCA cross-sectional area and
diameter (repetition time (TR)¼ 27ms; echo time
(TE)¼ 3.4ms; ﬂip angle (FA)¼ 20; matrix¼ 384
256, ﬁeld of view (FOV)¼ 210 210mm, slice thick-
ness (ST)¼ 1.2mm)
2. A sagittal single-slice 2D electrocardiogram triggered
phase-contrast (PC) MRA was performed to enable
estimation of the MCA ﬂow velocity (TR¼ 33ms;
TE¼ 5.3ms; FA¼ 30; matrix¼ 256 192, FOV¼
160 160mm, ST¼ 5mm, velocity encoding param-
eter (VENC)¼ 150 cm/s). The sagittal slice was cen-
tered 1 cm proximal to the bifurcation of the right
MCA. The acquisition window was sampled with 25
phases.
3. 3D PC magnetic resonance venography (MRV) of the
dural venous sinuses was performed to enable estima-
tion of the volumes of the superior sagittal and trans-
verse venous sinuses (TR¼ 12ms; TE¼ 4ms;
FA¼ 8; matrix¼ 352 224, FOV¼ 240 204mm;
acquired ST¼ 1.6mm; reconstructed ST¼ 0.8mm).
4. T2*-based susceptibility-weighted imaging (SWI) of
the whole brain (SWAN sequence, (susceptibility-
weighted angiography) provided by GE Healthcare,
Buckinghamshire, UK) was performed to assess
changes in the deep cerebral venous anatomy
(TR¼ 42ms; TE¼ 24.7ms; FA¼ 15; matrix¼
320 224, FOV¼ 220 200mm; acquired ST¼
2.6mm; reconstructed ST¼ 1.3mm).
5. Diﬀusion-weighted images of the whole brain
(TR¼ 10,000ms; TE¼ 95ms; matrix¼ 256 256;
FOV¼ 240 240mm; ST¼ 4.0mm; b¼ 0, 800,
1000) were acquired at each time point, from
which apparent diﬀusion coeﬃcient (ADC) maps
were calculated to assess for edema.
6. T1-based 3D fast spoiled gradient echo imaging
(FSPGR) of the whole brain was performed to enable
estimation of brain and CSF volume (TR¼ 7.8ms;
TE¼ 3ms; FA¼ 12; matrix¼ 256 256; FOV¼
220 165mm; acquired ST¼ 2.6mm; reconstructed
ST¼ 1.3mm).
Image analysis
The 3D TOF MRA data were imported into a GE
Advantage Workstation 4.6 (GE Healthcare,
Buckinghamshire, UK) to estimate the MCA diameter
and cross-sectional area. Three raters who were blinded
to the subject and time point at which the scan had been
acquired, undertook the measurements independently.
The M1 segment of the MCA was identiﬁed bilaterally
using the orthogonal multiplanar reconstruction
(MPR) module and each MCAM1 segment was manu-
ally divided into ﬁve equally spaced data points. The
cross-sectional view, the maximal diameter and cross-
sectional area were manually measured at each data
point in bilateral MCA M1 segments. A mean value
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for the MCA diameter and cross-sectional area at each
time point was calculated from the 10 data points.
The 2D PC-MRA data were also imported into the
GE Advantage Workstation 4.6. MCA ﬂow velocities
were obtained using the ﬂow analysis module. The
MCA margins were deﬁned automatically and adjusted
manually for each phase if necessary. Mean and peak
systolic ﬂow velocities were determined automatically
by the ﬂow analysis module.
Analyze 11.0 (AnalyzeDirect, KS, USA) was used to
calculate the total volumes of the superior sagittal and
transverse venous sinuses using the 3D PC-MRV data
acquired at each time point. The semi-automatic
threshold technique (using standardized minimum and
maximum threshold values) was used to deﬁne and
extract the appropriate venous sinuses to enable auto-
mated volume calculation.
The deep venous space was calculated in by
quantifying the total volume of all voxels correspond-
ing with deep veins within the brain tissue, which have
low signal intensity on SWI. SWI were segmented to
remove the skull and CSF using SPM8 (Wellcome
Trust Centre for Neuroimaging, University College,
London, UK). Using a Matlab (Mathworks Inc.,
Cambridge, UK) program written in-house, a linear
intensity normalization of the voxel data was per-
formed to correct for global intensity variations
between time points. Voxels falling within a user
deﬁned intensity window (Figure 1) were summed and
used to calculate the deep venous space based on the
voxel dimensions. The 2-h time point was used as a
baseline for these measurements due to an expected
increase from baseline to 2 h caused by the magnetic
susceptibility of deoxyhemoglobin (the BOLD eﬀect).
ADC maps were calculated after importing the
diﬀusion-weighted images into the GE Advantage
Workstation 4.6. Circular regions of interest (ROI) of
1 cm2 were placed bilaterally within the frontal white
matter, lentiform nuclei (gray matter), occipital white
matter, cerebellar white matter, and the genu and sple-
nium of the corpus callosum. The mean ADC value
within each right and left circular ROI was then calcu-
lated. The right and left ADC values for a given ana-
tomical region were averaged to give a single mean
ADC value for the region.
The T1-weighted 3D FSPGR data were imported
into the FMRIB Software Library (FSL) 5.0 (FMRIB
Group, Oxford, UK) to quantify brain parenchymal
and CSF volumes. Initially, the Brain Extraction Tool
(BET) was used to delete all non-brain tissue. The
FMRIB’s Automated Segmentation Tool (FAST) was
then used to segment the brain image into diﬀerent
tissue types (gray matter, white matter, and CSF).
This tool also automatically corrects for any spatial
intensity variations. Tissue volume quantiﬁcation was
carried out using the FSLSTATS command for each of
the segmented tissue images at each time point.
Statistical analysis
Analysis of repeated observations was performed using
the linear mixed models procedure in SPSS v22 (IBM,
NY, USA) to examine the eﬀects of time exposed to
hypoxia on each dependent variable. The linear mixed
models procedure does not require a balanced design so
is able to account for all missing data. Model param-
eters were estimated using the restricted maximum like-
lihood method and covariance was modeled as
unstructured. Sidak’s adjustment for multiple pairwise
comparisons and paired t-tests were employed as
appropriate. Study size was in part determined by
power calculations but also based upon similar studies.
To assess the relationship of selected variables, bivari-
ate correlations for ordinal data (Spearman’s Rho) and
continuous data (Pearson’s correlation) were used as
appropriate. Statistical signiﬁcance was set at p 0.05.
Results
Two of the 12 subjects were unable to complete the
study due to severe AMS and had to be withdrawn
after the 11-h time point. The data set was otherwise
complete. Changes in the basic physiological variables
with time exposed to normobaric hypoxia are displayed
in Table 1, and Table 2 presents changes in the mea-
sured radiological variables at each time point. Both
tables summarize the estimated marginal means of the
Figure 1. A histogram demonstrating voxel intensities for the
whole brain for all subjects at the specific time points. The
number of voxels falling below the vertical dashed line (the set
threshold level) was calculated to enable venous space
quantification.
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measured variables, conﬁdence intervals, and the sig-
niﬁcance of change at each time point.
Ten of the 12 subjects (including the two who left the
study early) developed a total Lake Louise score of 3 or
more at any individual time point (i.e. had a diagnosis
of AMS). The mean total Lake Louise and headache
scores for all subjects were seen to rise steadily at each
time point, with the largest increase at 22 h.
SpO2 and ETCO2 signiﬁcantly decreased at all hyp-
oxic time points compared to baseline, whereas the
heart rate rose signiﬁcantly at all-time points compared
to baseline (p< 0.001 for each of the three variables).
The systolic and diastolic blood pressures appeared to
steadily rise, although this trend was not statistically
signiﬁcant (p¼ 0.085 and 0.068, respectively). No sig-
niﬁcant changes in any of the venous blood compo-
nents were seen.
The mean MCA ﬂow velocity increased and peaked
after 2 h of continuous hypoxia exposure (47.53 to
57.09 cm/s; p¼ 0.05) before falling towards baseline
values for the remainder of the study. The MCA diam-
eter displayed a similar trend of an early rise before
decreasing, although this was not statistically signiﬁ-
cant (p¼ 0.065). The calculated mean ﬂow through
the MCA did not increase or decrease signiﬁcantly
over the 22-h course of the study when analyzed
using the linear mixed models procedure. However,
performing paired t-test analyses showed that the
mean MCA ﬂow rose signiﬁcantly from 4.5 to
6.1ml/s (p< 0.05) between the baseline and 2 h before
falling towards baseline values. The calculated BOC
was consistently low at all-time points compared to
the normoxic, baseline levels (p< 0.001). Calculated
COD did not change signiﬁcantly throughout the hyp-
oxic period.
The superior sagittal and transverse venous sinus
volumes did not change signiﬁcantly in response to
the prolonged hypoxic challenge. However, by 22 h,
there appeared to be an element of venocompression
at the level of the small, deep cerebral veins (116 cm3
at 2 h to 97 cm3 at 22 h; p< 0.05).
A late increase in total brain parenchymal volume
was seen at 22 h compared to baseline (1253ml at base-
line to 1282ml at 22 h; p< 0.05). Increases in both gray
matter (679ml at baseline to 695ml at 22 h; p< 0.05)
and white matter (574ml at baseline to 585ml at 22 h;
p< 0.001) volumes contributed to the overall brain
parenchymal volume increase. A compensatory signiﬁ-
cant decrease in total intracranial CSF was seen at 22 h
compared to baseline (284ml to 270ml; p< 0.05). In
addition, the increase in total brain parenchymal
volume correlated strongly with the decrease in CSF
volume between 0 and 22 h (Pearson¼0.67,
p< 0.05) (Figure 2). Strong correlation was seen
between the increase in white matter volume at 22 h
and the cumulative Lake Louise score for each patient
at 22 h (Spearman rho¼ 0.65, p< 0.05) (Figure 3). No
signiﬁcant correlation was observed between any other
variable and the headache or Lake Louise score.
Taking into account all the ADC ROIs at each time
point, a signiﬁcant rise in the mean whole brain ADC
value was observed after exposure to 11 and 22 h of hyp-
oxia (8.9 104 to 9.2 104 and 9.4 104mm2/s,
respectively; p< 0.001). With each regional ROI ana-
lyzed separately, there were signiﬁcant rises compared
to baseline in the ADC value within the genu
(16.9 104 at baseline to 18.3 104mm2/s at 22 h;
p< 0.001) and the splenium (20.3 104 at baseline to
22.8 104 at 11 and 21.9 104mm2/s at 22 h;
p< 0.001). The rest of the ROIs did not display any
signiﬁcant increases or decreases in ADC value over
time, although there was an upward trend within the
occipital lobes (6.19 104 at baseline to
6.47 104mm2/s; p¼ 0.06).
Discussion
The novel feature of this study is that arterial inﬂow,
large and small vessel venous outﬂow, cerebral edema
(ADC), brain parenchymal volumes, and intracranial
CSF volumes have been measured repeatedly and sim-
ultaneously over a 22-h period of sustained hypoxia.
As a consequence, this study gives insights into the
time course of both the adaptive processes as well as
some of the potentially maladaptive processes on acute
exposure to a FiO2¼ 0.12 (which is equivalent to
approximately 4400m). This is one of the ﬁrst studies
to use 3T MRI scanning for more than 10 h and this is
important as many of the more severe high-altitude
syndromes develop over a longer period of time – clas-
sically after a night at the new altitude.
This combination of time (including overnight) and
simulated altitude represents the sort of stimulus that
would be expected to cause a signiﬁcant level of acute
high-altitude illness and this was found to be the case
with most of the subjects. Ten of the 12 subjects devel-
oped a total Lake Louise score of more than 3 (in
keeping with a diagnosis of ‘AMS’). The mean total
Lake Louise and headache scores for all subjects were
seen to rise steadily at each time point, with the largest
increase at 22 h. COD was maintained by increases in
MCA velocity and there is emerging evidence that there
is also an associated increase in MCA diameter.8,18,19
This is the ﬁrst time that COD has been shown to be
maintained to 22 h when assessed by MR.
Late rises in ADC values within the genu and sple-
nium of the corpus callosum conﬁrm the build-up of
regional water content and are an indirect measure of
cerebral edema. This supports the ﬁndings observed by
Hackett et al.12 We found the observed increase in
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brain parenchymal volumes at 22 h was associated with
decreased brain CSF volumes (conﬁrming ‘‘internal
validation’’ of our methodology of independently mea-
suring the segmented CSF and brain parenchymal vol-
umes) and also a reduction in small venous vessel
volumes (SWI sequence) at 22 h, further increasing
the Starling pressure driving edema formation. A
decreased ability to buﬀer these parenchymal brain
volume changes will be reﬂected by rises in ICP and
eventually HACE.3 Interestingly, a correlation was
found between the cumulative Lake Louise score and
an increase in brain white matter volume at 22 h. This
study supports certain aspects of the recent Lawley
et al.20 publication where they found an increase in
brain volume (predominantly in the gray matter) at
10 h, with an associated fall in the cerebral component
of CSF. They also found a statistically signiﬁcant rela-
tionship between change in ICP (measured non-inva-
sively by MRI) and AMS severity (R2¼ 0.71, B¼ 2.3,
p< 0.01) after 10 h. We studied our subjects for a fur-
ther 12 h and found, as would be predicted, higher
levels of AMS symptoms. In addition, we found a
later increase in total brain parenchymal volume (gray
and white matter) at 22 h compared to baseline.
This study has shown for the ﬁrst time a possible
mechanistic link between hypoxia, increased arterial
inﬂow, a hypothesized rise in Starling pressures, and
the subsequent development of parenchyma brain
edema and the clinical development of AMS. We,
therefore, propose a uniﬁcation hypothesis, which
involves the activation of train of etiologic factors pro-
gressing from cerebral arterial to venous to parenchy-
mal compartments, and also a clear staged time course
(Figure 4):
1. Firstly, hypoxia results in increased CBF (in order to
maintain COD).8
2. The increased arterial inﬂow is associated with an
increase in venous outﬂow. The increase in venous
outﬂow requires increased ‘‘driving pressures’’ to
maintain CBF (raised arterial pressures).21
3. The venous outﬂow restriction or resistance could
take place at a number of levels (Figure 5):
a. Intracerebral as appears to be the case in this
study, which has not been demonstrated
previously.
b. Intracranial (in the great veins and dural venous
sinuses).16
Figure 2. A graph demonstrating the correlation between the percentage change of the total intracranial CSF volume and the total
brain parenchymal volume over the 22-h study period.
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c. Extracranially (elevated CVP, anatomic venous
restrictions).3,22
The required increase in ‘‘driving pressure’’ will in
turn perturbate ‘‘Starling pressures’’ and is likely to be
a contributing factor in the formation of parenchymal
edema. As edema develops, there will be further restric-
tion in venous outﬂow and this could result in a dan-
gerous positive feedback loop. Reduction of the
cerebral capacitance will eventually occur resulting in
an increase in ICP and, ultimately, AMS/HACE. The
increased CBF will increase the likelihood of vasogenic
edema3,19 and localized cellular hypoxia makes cells
susceptible to cytotoxic edema.23,24 It should be noted
that in this study the ‘‘venous outﬂow restriction’’
appears to be associated with smaller venous vessels
rather than the large vessels / anatomical variants
described by Wilson et al.16 (who found that restriction
in transverse venous sinus outﬂow was associated with
more headaches and proximal venous distension
between 90 and 180min of exposure to 12% oxygen).
The observed decreasing trend for transverse venous
sinus volumes in the current study was modest without
reaching signiﬁcance and, therefore, could be attributed
to a small study sample.
The experimental design using a hypoxic tent adja-
cent to the MRI room functioned well. Subjects were
comfortable, were kept well hydrated and in constant
communication with the investigators throughout the
time of exposure to hypoxia. Care was taken to main-
tain hypoxia while transferring from the tent to the
scanner and during the period of the scan.
Study limitations
Limitations of this study include a small but stable
accumulation of carbon dioxide in the tent, despite
soda lime scrubbers, which may have contributed to
the increase in peak systolic ﬂow velocity in the
MCA. However, during scanning, re-breathing was
not an issue and there were low ETCO2 readings.
There were a relatively small number of subjects for
investigation of a variable condition such as AMS
with symptoms usually occurring 6–12 h after arrival
at high altitude. However, peak symptoms would be
expected to occur somewhat later after 24 h exposure.
Nevertheless, two subjects were withdrawn after 11 h of
Figure 3. A graph demonstrating the correlation between the percentage volume change of the brain white matter and the
cumulative Lake Louise score at 22 h.
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hypoxia and signiﬁcant symptoms occurred in the
remainder. As the subjects were all young, results
cannot necessarily be extrapolated to older people. In
most reports, young subjects are more prone to develop
AMS.25 One theory that older people with more age-
related atrophy might tolerate cerebral swelling better
has been suggested.
Wider clinical relevance
The results of this study may have important transla-
tional implications.26 ICP is the primary neurological
parameter that guides therapy on neurointensive care.
Understanding the cerebrovascular interactions that
eﬀect ICP is vital in the management of both trauma
and stroke patients. The optimization of cerebral per-
fusion pressure (CPP) is determined by ICP
(CPP¼Mean Arterial Pressure – ICP). Intracranial
venous outﬂow pressure closely correlates with ICP.27
The eﬀects of carbon dioxide and hyperventilation
on CBF are well known.28 The eﬀects of hypoxia, and
in particular the changes that occur over a period of
time, may aid the understanding of the interplay
between chest and intracranial physiology. Hypoxia,
for example secondary to chest sepsis or adult respira-
tory distress syndrome is common in the neurocritical
patient.29 As such, the management of cerebral oxygen-
ation, as well as carbon dioxide are integral to good
neurocritical care and is likely to be crucial to optimiz-
ing the correct therapeutic regime.
In this study, hypoxia resulted in parenchymal brain
swelling. Subsequent development of cerebral edema
was found, which would eventually result in a rise in
ICP. This was attributed to compression of the cerebral
venous system, restricting venous outﬂow, and possibly
a Starling resistor mechanism.30 In an animal model,
venous hypertension has been associated with increases
in brain volume and this was caused by vessel dilata-
tion. Cerebral edema only occurred if there was also
associated cerebral tissue injury.31 Acute hypoxia can
cause tissue injury through a number of diﬀerent mech-
anisms such as direct damage to basal membrane struc-
tures,32 VEGF,24 or free radicals.25
Interestingly, there is corroborative clinical evidence.
It has been shown in a study of sub-arachnoid hemor-
rhage (SAH) patients that increased ICP values
Figure 4. A diagram illustrating the proposed sequence of events thought to contribute towards the development of AMS.
Source: Wilson MH and Imray CHE. The cerebral venous system and hypoxia. J Appl Physiol.Epub ahead of print 20 August 2015.DOI:
10.1152/japplphysiol.00327.2015.
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correlated with increased venous ﬂow velocities and
were associated with poor outcome.33 Flow velocity
of the transversal sinus was thought to be a highly sen-
sitive, reliable, and early predictor of outcome in SAH.
An explanation is that raised ICP would reduce intra-
cerebral venous diameters and in turn, if CBF were to
be maintained, a rise in venous velocities would be
expected and this would result in changes in
the Starling pressures at the capillary level.
Conclusions
In conclusion, this 22-h study has used a variety of MR
imaging techniques to document the development of
HACE in normal individuals. There was an early
increase in CBF which maintained COD. Mild clinical
symptoms appeared after a few hours and these grad-
ually increased in severity over time. Cerebral edema
developed later and this occurred in conjunction with
an increase in the brain parenchyma volumes and a
reduction in CSF volumes. Inability to buﬀer this
brain swelling would result in rises in ICP and this is
likely to be associated with deterioration in the patient’s
condition. A possible novel mechanism involving local
edema causing a reduction in post capillary venous
diameters has been observed. In order to maintain the
high CBF through smaller vessels, there must be alter-
ations in the Starling pressures, and these could be one
of the causative factors, in parallel with reduced cere-
bral buﬀering, in the development of life threatening
raised intracerebral pressures seen in HACE. The
same mechanism may be implicated in raised ICP
from other causes.
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Figure 5. A diagram illustrating the intracranial and extracranial sources thought to contribute to venous outflow restriction.
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